Compared to BRAF wild-type BHP 2-7 cells, BRAF inhibitor dabrafenib preferentially inhibited ERK signaling and thyroid cancer cell proliferation, arrested cell circle, and regulated iodine and glucose-handling gene expression in BRAFV600E-positive PTC cells. Here, BRAF is linked to thyroid cancer.